Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Sana Biotechnology
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Fujifilm and Sana Biotechnology Enter Cell Therapy Partnership
Details : FUJIFILM Cellular Dynamics grants Sana a non-exclusive license under intellectual property rights owned or controlled by FUJIFILM Cellular Dynamics, and will provide iPSC cell lines (including research-grade and/or Good Manufacturing Practices (GMP)-grad...
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 16, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Sana Biotechnology
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Fujifilm To Restart Clinical Trial of Avigan to Treat Covid-19: Media
Details : Japan has approved Avigan, known generically as favipiravir, as an emergency flu medicine. But concerns remain, as the drug has been shown to cause birth defects in animal studies and its effectiveness against COVID-19 has proven difficult to demonstrate...
Product Name : Avigan
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 21, 2021
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Fujifilm's Avigan Shows No Significant Benefit on Covid-19 Mortality: Study
Details : The meta-analysis of nine clinical trials showed the drug, known generically as favipiravir, helped patients early on in their hospitalisation but failed to demonstrate statistically significant results in reducing mortality among those with mild to mode...
Product Name : Avigan
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 18, 2021
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Japan Govt Board: Data on Efficacy of Covid-19 Drug Candidate Avigan Is Inconclusive
Details : The Japanese Health Ministry said on Monday its medical review board concluded that clinical trial data to determine the efficacy of Fujifilm Holdings Corp’s COVID-19 drug candidate Avigan is inconclusive.
Product Name : Avigan
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 21, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Japan Expects to Launch Clinical Trials Of Covid-19 Vaccine in July
Details : Government of Japan intends to approve Fujifilm’s anti-flu drug Avigan by the end of this May 2020 for the treatment of patients suffering from Covid-19 infection.
Product Name : Avigan
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 05, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Appili Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Details : Appili Therapeutics to sponsor first clinical program in the world designed to assess the use of FUJIFILM Toyama Chemical’s favipiravir for COVID-19 as prophylaxis for outbreak control.
Product Name : Avigan
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 05, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Appili Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FUJIFILM conducted a phase III trial in Japan for COVID-19 patients with non-severe pneumonia. Based on the results, it seeks to add, indication as well as dosage and administration concerning COVID-19 to the current manufacturing and marketing approval ...
Product Name : Avigan
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 16, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Fujifilm's Avigan Inconclusive in COVID-19 Patients in Japan Trial
Details : Although patients given the drug early in the trial showed more improvement than those who got delayed doses, the results did not reach statistical significance.
Product Name : Avigan
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 07, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The efficacy primary endpoint is time to negative conversion of detectable SARS-CoV 2 viral RNA in the RT-PCR assays, and to alleviation of symptoms (body temperature, oxygen saturation and chest images).
Product Name : Avigan
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 23, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The clinical trial in the U.S. will enroll approximately 50 patients with COVID-19, in collaboration with Brigham and Women’s Hospital, and other hospitals.
Product Name : Avigan
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 04, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable